AbbVie Inc.
ABBV
$236.19
$2.331.00%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 61.16B | 59.64B | 58.33B | 57.37B | 56.33B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 61.16B | 59.64B | 58.33B | 57.37B | 56.33B |
| Cost of Revenue | 17.36B | 17.02B | 16.77B | 16.63B | 16.69B |
| Gross Profit | 43.80B | 42.62B | 41.56B | 40.74B | 39.65B |
| SG&A Expenses | 13.64B | 13.51B | 14.13B | 14.26B | 14.10B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -24.00M | -31.00M | -31.00M | -7.00M | -7.00M |
| Total Operating Expenses | 40.05B | 39.29B | 39.43B | 39.26B | 38.91B |
| Operating Income | 21.12B | 20.36B | 18.89B | 18.11B | 17.42B |
| Income Before Tax | 6.60B | 1.66B | 3.03B | 3.62B | 3.72B |
| Income Tax Expenses | 2.36B | -735.00M | -741.00M | -581.00M | -570.00M |
| Earnings from Continuing Operations | 4.23K | 2.40K | 3.77K | 4.20K | 4.29K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -7.00M | -7.00M | -8.00M | -8.00M | -8.00M |
| Net Income | 4.23B | 2.39B | 3.76B | 4.20B | 4.28B |
| EBIT | 21.12B | 20.36B | 18.89B | 18.11B | 17.42B |
| EBITDA | 29.25B | 28.61B | 27.16B | 26.46B | 25.81B |
| EPS Basic | 2.36 | 1.33 | 2.11 | 2.35 | 2.40 |
| Normalized Basic EPS | 6.65 | 6.38 | 5.89 | 5.68 | 5.50 |
| EPS Diluted | 2.36 | 1.32 | 2.10 | 2.35 | 2.40 |
| Normalized Diluted EPS | 6.64 | 6.37 | 5.88 | 5.67 | 5.49 |
| Average Basic Shares Outstanding | 7.08B | 7.07B | 7.07B | 7.07B | 7.08B |
| Average Diluted Shares Outstanding | 7.09B | 7.08B | 7.08B | 7.08B | 7.09B |
| Dividend Per Share | 6.65 | 6.56 | 6.47 | 6.38 | 6.29 |
| Payout Ratio | 275.84% | 481.49% | 301.30% | 266.46% | 257.71% |